✉news TechnologyTechnology first seen 2 d ago, last 2 d ago, peak #30
AbbVie signs $757m migraine drug deal with Brise Pharmaceuticals
Original: AbbVie inks $757m migraine-focused deal with Brise Pharmaceuticals
AbbVie has agreed a deal worth up to $757m with Brise Pharmaceuticals focused on migraine treatments. The agreement covers development work in a field where AbbVie already markets major therapies, including Botox for chronic migraine and the CGRP blocker Qulipta. Financial details beyond the headline value were not disclosed in initial reports, and the specific assets involved have not yet been named publicly.
Why now: The deal signals AbbVie's continued investment in the lucrative migraine market, drawing attention from pharma investors and analysts.
Evidence
- AbbVie inks $757m migraine-focused deal with Brise Pharmaceuticals · Pharmaceutical Technology
API: https://socialmediatrends-api.osmike.com/v1/trends/4765104